Meeting
2015 Gastrointestinal Cancers Symposium
Phase II trial of temsirolimus (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC).
Authors
Robin Kate Kelley
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Robin Kate Kelley , Halla Sayed Nimeiri , John Dozier Gordan , Jimmy Hwang , Ryan M. McWhirter , Advaita Kanakamedala , Chloe Evelyn Atreya , Laura Kulik , Sheetal Kircher , Mary Frances Mulcahy , Al Bowen Benson III, Alan P. Venook
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01687673
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr TPS501)
DOI
10.1200/jco.2015.33.3_suppl.tps501
Abstract #
TPS501
Poster Bd #
F16
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus.
First Author: Robin Kate Kelley
Poster
2018 Gastrointestinal Cancers Symposium
A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC).
First Author: Lipika Goyal
Poster
2014 ASCO Annual Meeting
Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).
First Author: Tudor-Eliade Ciuleanu
Poster
2022 ASCO Annual Meeting
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel